Project Grant R21CA302901
Award Date 5/13/26
Completion Date 4/30/28
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $640,135 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025 through July 31, 2030. This award supports the development of next-generation menin inhibitors designed to overcome clinical resistance observed in acute myeloid leukemia (AML) patients undergoing menin inhibitor therapy. The research addresses the critical clinical problem of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Maryland, Baltimore a $2.84M Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate improved cancer treatment methodologies. The award, effective August 18, 2025 through July 30, 2029, funds research focused on enhancing the therapeutic efficacy of cyclophosphamide (CPA) and doxorubicin (DOX)-based chemotherapy regimens while minimizing treatment-related toxicity....
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $646,881 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2031. The award supports the development of first-in-class small molecule inhibitors targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase protein implicated in acute leukemia pathogenesis. The research focuses on creating selective...
- Federal Grant Award Summary The National Cancer Institute, under the Cancer Treatment Research program (CFDA 93.395), awarded a $700,338 Project Grant to the Regents of the University of California, San Francisco (UCSF) effective May 11, 2026, with completion targeted for April 30, 2031. This research initiative focuses on identifying and validating resistance mechanisms to asciminib, the first allosteric tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML) treatment....
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Minnesota a $395,973 Project Grant on September 5, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop deazaflavin analog compounds as selective multidrug resistance protein 1 (MRP1) inhibitors for cancer chemosensitization. The research addresses multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transporters, which represents a major barrier to effective...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Michigan a $646,920 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning March 11, 2026, with completion targeted for February 28, 2031. This award supports research into novel multi-targeted therapeutic strategies to address chemotherapy-resistant T-cell lymphomas (TCL) and their tumor microenvironment. The research addresses critical treatment gaps by investigating mechanisms of...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 11, 2025 through August 31, 2030. The project, "Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells," focuses on fundamental research to understand and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs). The...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded April 1, 2026, with completion scheduled for March 31, 2028. The award supports research investigating dual-targeting therapeutic strategies for acute myeloid leukemia (AML) by combining BCL-2 inhibition with CD123-directed natural killer (NK) cell engager immunotherapy. The research will evaluate the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...